Lerodalcibep: First Approval
Related Experiment Video
Updated: Apr 8, 2026

Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
Amy Zhuang-Yan1, Hannah A Blair2
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Abstract:
Lerodalcibep (lerodalcibep-liga; LEROCHOL®), a subcutaneously administered third-generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, is being developed by LIB Therapeutics for the treatment of hypercholesterolaemia. Lerodalcibep received its first approval on 12 December 2025 in the USA, as an adjunct to diet and exercise, to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia. Lerodalcibep is in preregistration for hypercholesterolaemia in the EU. Lerodalcibep is administered as a once-monthly subcutaneous injection. This article summarizes the milestones in the development of lerodalcibep leading to this first approval for the treatment of adults with hypercholesterolaemia.
More Related Videos
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drugs for Treatment of Constipation-Predominant IBS
Clinically Relevant Drug Product Specifications: Methods of Establishment
Drug Regulation

